Beone Medicines Ltd.(688235)

277.92+1.09+0.39%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

Company Profile
Company Name
百济神州有限公司
Industry
医药制造业
Listing Date
2021-12-15
Registered Capital
15万元
Introduction
百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。

1D
5D
Day
Week
Month

Loading ...

High

279.23

Open

276.91

T/O Rate

1.14%

Low

274.74

Close

276.83

Amplitude

1.62%

Most Discussed

{"pagemeta":{"title":"Beone Medicines Ltd.(688235),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Beone Medicines Ltd.(688235) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Beone Medicines Ltd.,688235,Beone Medicines Ltd.股票,Beone Medicines Ltd.股票老虎,Beone Medicines Ltd.股票老虎国际,Beone Medicines Ltd.行情,Beone Medicines Ltd.股票行情,Beone Medicines Ltd.股价,Beone Medicines Ltd.股市,Beone Medicines Ltd.股票价格,Beone Medicines Ltd.股票交易,Beone Medicines Ltd.股票购买,Beone Medicines Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Beone Medicines Ltd.(688235),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Beone Medicines Ltd.(688235) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}},"tab":"community","symbol":"688235","data":{"stockData":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"Beone Medicines Ltd.","latestPrice":277.92,"timestamp":1766559601000,"preClose":276.83,"halted":0,"volume":1313519,"delay":0,"changeRate":0.0039,"floatShares":114999999,"shares":1541000000,"eps":-0.0994,"marketStatus":"Closed","change":1.09,"latestTime":"12-24 15:00:01","open":276.91,"high":279.23,"low":274.74,"amount":364000000,"amplitude":0.0162,"askPrice":277.93,"askSize":4,"bidPrice":277.92,"bidSize":10,"shortable":0,"etf":0,"ttmEps":-0.0994,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766626200000},"marketStatusCode":5,"adr":0,"adjPreClose":276.83,"symbolType":"stock_kcb","openAndCloseTimeList":[[1766539800000,1766547000000],[1766552400000,1766559600000]],"highLimit":304.51,"lowLimit":249.15,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1540677809,"isCdr":false,"pbRate":14.6,"roa":"--","roe":"4.26%","epsLYR":-3.64,"committee":-0.630695,"marketValue":428185000000.0001,"turnoverRate":0.0114,"status":0,"afterMarket":{"amount":0,"volume":0,"close":277.92,"buyVolume":0,"sellVolume":0,"time":1766561639585,"indexStatus":"Closed 12-24 15:30:00","preClose":276.83},"hkstockBrief":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"BEIGENE","latestPrice":183.5,"timestamp":1766549304006,"preClose":184,"halted":0,"volume":1233686,"delay":0,"premium":"-40.54"},"floatMarketCap":31976000000},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.408037053010600","cardData":[{"tweetId":"408037053010600","author":{"authorId":"4199778986251352","idStr":"4199778986251352","name":"只想打游戏和搞钱的Leo","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"<a href=\"https://laohu8.com/S/ONC\">$百济神州(ONC)$</a>&nbsp;","plainDigest":"$百济神州(ONC)$","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1740633797545,"gmtModify":1740634256272,"symbols":["ONC","688235","06160"],"themeIds":["7516f9ef7e8042739b8597466da26fe7"],"themes":[{"themeId":"7516f9ef7e8042739b8597466da26fe7","themeType":0,"name":"Winning Trades"}],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/d79a64bce2146d0eaeaa64d433f0834f","width":"972","height":"1631"}],"repostCount":0,"viewCount":389,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://ttm.financial/post/408037053010600","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"upFlag":false,"length":15,"displayRows":2,"strategy":"timeline","foldSize":0,"authorId":"4199778986251352"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.402507489046856","cardData":[{"tweetId":"402507489046856","author":{"authorId":"3494821977906691","idStr":"3494821977906691","name":"天晴路平","avatar":"https://static.tigerbbs.com/4596fe728b767c77b621ceb983338874","userType":1,"introduction":"","crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"<a href=\"https://laohu8.com/S/ONC\">$百济神州(ONC)$</a>&nbsp;","plainDigest":"$百济神州(ONC)$","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1739286902532,"gmtModify":1739287861415,"symbols":["ONC","688235","06160"],"themeIds":["7516f9ef7e8042739b8597466da26fe7"],"themes":[{"themeId":"7516f9ef7e8042739b8597466da26fe7","themeType":0,"name":"Winning Trades"}],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/66feefe7f5a486bc19288932b9aac49b","width":"1092","height":"1717"}],"repostCount":0,"viewCount":550,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://ttm.financial/post/402507489046856","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"upFlag":false,"length":15,"displayRows":2,"strategy":"timeline","foldSize":0,"authorId":"3494821977906691"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.305364893655184","cardData":[{"tweetId":"305364893655184","author":{"authorId":"4103332230805300","idStr":"4103332230805300","name":"Smartkarma","avatar":"https://community-static.tradeup.com/news/39fffba2ff205c2730b5bf07e3de6647","userType":5,"introduction":"https://on.skr.ma/free4tiger","crmLevel":0,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1888,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"BeiGene (6160.HK/BGNE.US/688235.CH) 24Q1- A Breakeven Point Is on the Horizon, but It Is Not Stable","digest":"⬆ $BeiGene (06160)$ - BeiGene's high product revenue growth in 24Q1 narrowed net loss, with potential for breakeven in 24Q4.This is an affirmation for BeiGene. Sustained overall profitability may not occur until 2026/2027 Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-6160-hk-bgne-us-688235-ch-24q1-a-breakeven-point-is-on-the-horizon-but-it-is-not-stable?utm_source=tiger_community By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On BeiGene (06160):- https://www.smartkarma.com/entities/beigene-ltd?utm_source=tiger_community","plainDigest":"⬆ $BeiGene (06160)$ - BeiGene's high product revenue growth in 24Q1 narrowed net loss, with potential for breakeven in 24Q4.This is an affirmation for BeiGene. Sustained overall profitability may not occur until 2026/2027 Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-6160-hk-bgne-us-688235-ch-24q1-a-breakeven-point-is-on-the-horizon-but-it-is-not-stable?utm_source=tiger_community By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On BeiGene (06160):- https://www.smartkarma.com/entities/beigene-ltd?utm_source=tiger_community","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1715561916000,"gmtModify":1715566586081,"symbols":["BGNE","LU0588546209.SGD","LU1969619763.USD","LU0307460666.USD","LU2328871848.SGD","06160","688235"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":56355,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://ttm.financial/post/305364893655184","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":597,"displayRows":2,"strategy":"timeline","foldSize":0,"authorId":"4103332230805300"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.304451286257688","cardData":[{"tweetId":"304451286257688","author":{"authorId":"4103332230805300","idStr":"4103332230805300","name":"Smartkarma","avatar":"https://community-static.tradeup.com/news/39fffba2ff205c2730b5bf07e3de6647","userType":5,"introduction":"https://on.skr.ma/free4tiger","crmLevel":0,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1888,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"BeiGene (BGNE US) - Consistently Exceeding Expectations","digest":"⬆ $BeiGene (BGNE)$ - Product sales continued beating expectation. In 1Q24, BeiGene recorded total product sales of US$747mn (+18% QoQ, +82% YoY), representing 25.7% of... Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-bgne-us-consistently-exceeding-expectations?utm_source=tiger_community By CMB International, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/cmb-international?utm_source=tiger_community On BeiGene (BGNE):- https://www.smartkarma.com/entities/beigene-ltd-b5b6d079-eb7e-41a8-9ac4-a391831e02f4?utm_source=tiger_community","plainDigest":"⬆ $BeiGene (BGNE)$ - Product sales continued beating expectation. In 1Q24, BeiGene recorded total product sales of US$747mn (+18% QoQ, +82% YoY), representing 25.7% of... Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-bgne-us-consistently-exceeding-expectations?utm_source=tiger_community By CMB International, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/cmb-international?utm_source=tiger_community On BeiGene (BGNE):- https://www.smartkarma.com/entities/beigene-ltd-b5b6d079-eb7e-41a8-9ac4-a391831e02f4?utm_source=tiger_community","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1715338745000,"gmtModify":1715345372299,"symbols":["BGNE","LU0588546209.SGD","LU1969619763.USD","LU0307460666.USD","LU2328871848.SGD","06160","688235"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":54386,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://ttm.financial/post/304451286257688","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":545,"displayRows":2,"strategy":"timeline","foldSize":0,"authorId":"4103332230805300"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.304126500954256","cardData":[{"tweetId":"304126500954256","author":{"authorId":"4103332230805300","idStr":"4103332230805300","name":"Smartkarma","avatar":"https://community-static.tradeup.com/news/39fffba2ff205c2730b5bf07e3de6647","userType":5,"introduction":"https://on.skr.ma/free4tiger","crmLevel":0,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1888,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"BeiGene Ltd - 1Q24: Strong revenue growth momentum continues","digest":"⬆ $BeiGene (06160)$ - In 1Q24, BeiGene’s revenue climbed 68% yoy to US$752m and net loss to shareholders narrowed to US$251m (US$363m in 1Q23). Revenue growth was led... Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-ltd-1q24-strong-revenue-growth-momentum-continues?utm_source=tiger_community By CGS CIMB Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/cgs-cimb-research?utm_source=tiger_community On BeiGene (06160):- https://www.smartkarma.com/entities/beigene-ltd?utm_source=tiger_community","plainDigest":"⬆ $BeiGene (06160)$ - In 1Q24, BeiGene’s revenue climbed 68% yoy to US$752m and net loss to shareholders narrowed to US$251m (US$363m in 1Q23). Revenue growth was led... Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-ltd-1q24-strong-revenue-growth-momentum-continues?utm_source=tiger_community By CGS CIMB Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/cgs-cimb-research?utm_source=tiger_community On BeiGene (06160):- https://www.smartkarma.com/entities/beigene-ltd?utm_source=tiger_community","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1715256118000,"gmtModify":1715260125420,"symbols":["BGNE","06160","688235"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":56387,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://ttm.financial/post/304126500954256","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":510,"displayRows":2,"strategy":"timeline","foldSize":0,"authorId":"4103332230805300"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.280857521184840","cardData":[{"tweetId":"280857521184840","author":{"authorId":"4103332230805300","idStr":"4103332230805300","name":"Smartkarma","avatar":"https://community-static.tradeup.com/news/39fffba2ff205c2730b5bf07e3de6647","userType":5,"introduction":"https://on.skr.ma/free4tiger","crmLevel":0,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1888,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"BeiGene (6160.HK/BGNE.US/688235.CH) - Pain Points Behind the High Growth","digest":"⬆ $BeiGene (06160)$ - Due to quick pick-up of expenses, breakeven is more challenging. BeiGene hasn't proved its profitability. If it indeed has a plan to turn loss into profits, cost control is the most basic “sincerity”. Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-6160-hk-bgne-us-688235-ch-pain-points-behind-the-high-growth?utm_source=tiger_community By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On BeiGene (06160):- https://www.smartkarma.com/entities/beigene-ltd?utm_source=tiger_community","plainDigest":"⬆ $BeiGene (06160)$ - Due to quick pick-up of expenses, breakeven is more challenging. BeiGene hasn't proved its profitability. If it indeed has a plan to turn loss into profits, cost control is the most basic “sincerity”. Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-6160-hk-bgne-us-688235-ch-pain-points-behind-the-high-growth?utm_source=tiger_community By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On BeiGene (06160):- https://www.smartkarma.com/entities/beigene-ltd?utm_source=tiger_community","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1709600473600,"gmtModify":1709602783756,"symbols":["BGNE","LU0588546209.SGD","LU1969619763.USD","LU0307460666.USD","LU2328871848.SGD","PCOM","06160","688235"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":54377,"likeCount":1,"liked":false,"collected":false,"commentCount":1,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://ttm.financial/post/280857521184840","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":567,"displayRows":2,"strategy":"timeline","foldSize":0,"authorId":"4103332230805300"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.278580319866952","cardData":[{"tweetId":"278580319866952","author":{"authorId":"4103332230805300","idStr":"4103332230805300","name":"Smartkarma","avatar":"https://community-static.tradeup.com/news/39fffba2ff205c2730b5bf07e3de6647","userType":5,"introduction":"https://on.skr.ma/free4tiger","crmLevel":0,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1888,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"BeiGene (BGNE US) – Expect a Productive 2024 for Early Pipeline Assets","digest":"⬆ $BeiGene (BGNE)$ - Strong sales momentum of zanubrutinib eased market concerns. In 4Q23, BeiGene recorded total product sales of US$631mn (+6% QoQ or +86% YoY). Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-bgne-us-expect-a-productive-2024-for-early-pipeline-assets?utm_source=tiger_community By CMB International, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/cmb-international?utm_source=tiger_community On BeiGene (BGNE):- https://www.smartkarma.com/entities/beigene-ltd-b5b6d079-eb7e-41a8-9ac4-a391831e02f4?utm_source=tiger_community","plainDigest":"⬆ $BeiGene (BGNE)$ - Strong sales momentum of zanubrutinib eased market concerns. In 4Q23, BeiGene recorded total product sales of US$631mn (+6% QoQ or +86% YoY). Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-bgne-us-expect-a-productive-2024-for-early-pipeline-assets?utm_source=tiger_community By CMB International, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/cmb-international?utm_source=tiger_community On BeiGene (BGNE):- https://www.smartkarma.com/entities/beigene-ltd-b5b6d079-eb7e-41a8-9ac4-a391831e02f4?utm_source=tiger_community","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1709043749956,"gmtModify":1709044454425,"symbols":["BGNE","LU0588546209.SGD","LU1969619763.USD","LU0307460666.USD","LU2328871848.SGD","06160","688235"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":53791,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://ttm.financial/post/278580319866952","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":551,"displayRows":2,"strategy":"timeline","foldSize":0,"authorId":"4103332230805300"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.275586099838992","cardData":[{"tweetId":"275586099838992","author":{"authorId":"4103332230805300","idStr":"4103332230805300","name":"Smartkarma","avatar":"https://community-static.tradeup.com/news/39fffba2ff205c2730b5bf07e3de6647","userType":5,"introduction":"https://on.skr.ma/free4tiger","crmLevel":0,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1888,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"BeiGene (6160.HK/BGNE.US/688235.CH) - 2023 Results Preview and Undervaluation Concerns","digest":"⬆ $BeiGene (06160)$ - BeiGene's sluggish share price could be related to geopolitical conflicts/weak market sentiment. But there’s no need for US to sanction China's biotech. We're optimistic about BeiGene's 2023 results. Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-6160-hk-bgne-us-688235-ch-2023-results-preview-and-undervaluation-concerns?utm_source=tiger_community By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On BeiGene (06160):- https://www.smartkarma.com/entities/beigene-ltd?utm_source=tiger_community","plainDigest":"⬆ $BeiGene (06160)$ - BeiGene's sluggish share price could be related to geopolitical conflicts/weak market sentiment. But there’s no need for US to sanction China's biotech. We're optimistic about BeiGene's 2023 results. Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-6160-hk-bgne-us-688235-ch-2023-results-preview-and-undervaluation-concerns?utm_source=tiger_community By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On BeiGene (06160):- https://www.smartkarma.com/entities/beigene-ltd?utm_source=tiger_community","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1708304421693,"gmtModify":1708309256164,"symbols":["BGNE","LU0588546209.SGD","LU1969619763.USD","LU0307460666.USD","LU2328871848.SGD","06160","688235"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":1,"viewCount":53969,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://ttm.financial/post/275586099838992","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":585,"displayRows":2,"strategy":"timeline","foldSize":0,"authorId":"4103332230805300"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.275247126556688","cardData":[{"tweetId":"275247126556688","author":{"authorId":"4103332230805300","idStr":"4103332230805300","name":"Smartkarma","avatar":"https://community-static.tradeup.com/news/39fffba2ff205c2730b5bf07e3de6647","userType":5,"introduction":"https://on.skr.ma/free4tiger","crmLevel":0,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1888,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"China Healthcare Weekly (Feb16)-Innovative Drug Is \"Innocent\" In Geopolitics, BeiGene's BTK, Jacobio","digest":"⬇ $Jacobio Pharmaceuticals(01167)$ - Due to US Draft Bill against CXO, Biotech's share price also plummeted, but they're \"Innocent\".Future BTK inhibitor market pattern shows the upper limit of BeiGene. Jacobio's outlook is not optimistic Continue reading on Smartkarma:- https://www.smartkarma.com/insights/china-healthcare-weekly-feb16-innovative-drug-is-innocent-in-geopolitics-beigene-s-btk-jacobio?utm_source=tiger_community By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On Jacobio Pharmaceuticals (01167):- https://www.smartkarma.com/entities/jacobio-pharmaceuticals?utm_source=tiger_community","plainDigest":"⬇ $Jacobio Pharmaceuticals(01167)$ - Due to US Draft Bill against CXO, Biotech's share price also plummeted, but they're \"Innocent\".Future BTK inhibitor market pattern shows the upper limit of BeiGene. Jacobio's outlook is not optimistic Continue reading on Smartkarma:- https://www.smartkarma.com/insights/china-healthcare-weekly-feb16-innovative-drug-is-innocent-in-geopolitics-beigene-s-btk-jacobio?utm_source=tiger_community By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On Jacobio Pharmaceuticals (01167):- https://www.smartkarma.com/entities/jacobio-pharmaceuticals?utm_source=tiger_community","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1708221664545,"gmtModify":1708221688024,"symbols":["BGNE","LU0588546209.SGD","LU1969619763.USD","HCSG","LU0307460666.USD","LU2328871848.SGD","06160","688235"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":54294,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://ttm.financial/post/275247126556688","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":638,"displayRows":2,"strategy":"timeline","foldSize":0,"authorId":"4103332230805300"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.251869829603520","cardData":[{"tweetId":"251869829603520","author":{"authorId":"4103332230805300","idStr":"4103332230805300","name":"Smartkarma","avatar":"https://community-static.tradeup.com/news/39fffba2ff205c2730b5bf07e3de6647","userType":5,"introduction":"https://on.skr.ma/free4tiger","crmLevel":0,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1888,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"BeiGene (BGNE US) – Three Synergistic Haematology BIC/FIC Molecules Showing Promising Data","digest":"⬆ $BeiGene (BGNE)$ - Additional studies presented at ASH indicated that zanu provided meaningful benefits for acalabrutinib-intolerant patients, which could lead to zanu’s global market share gain, in our view. Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-bgne-us-three-synergistic-haematology-bic-fic-molecules-showing-promising-data?utm_source=tiger_community By CMB International, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/cmb-international?utm_source=tiger_community On BeiGene (BGNE):- https://www.smartkarma.com/entities/beigene-ltd-b5b6d079-eb7e-41a8-9ac4-a391831e02f4?utm_source=tiger_community","plainDigest":"⬆ $BeiGene (BGNE)$ - Additional studies presented at ASH indicated that zanu provided meaningful benefits for acalabrutinib-intolerant patients, which could lead to zanu’s global market share gain, in our view. Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-bgne-us-three-synergistic-haematology-bic-fic-molecules-showing-promising-data?utm_source=tiger_community By CMB International, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/cmb-international?utm_source=tiger_community On BeiGene (BGNE):- https://www.smartkarma.com/entities/beigene-ltd-b5b6d079-eb7e-41a8-9ac4-a391831e02f4?utm_source=tiger_community","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1702522985458,"gmtModify":1702522985495,"symbols":["BGNE","688235","06160"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":53524,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://ttm.financial/post/251869829603520","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":615,"displayRows":2,"strategy":"timeline","foldSize":0,"authorId":"4103332230805300"}],"position":0}],"size":10,"extra":{"requestId":"c1b3845d7829478583550ae3dc9a61a6"}},"newsData":null,"noticeData":{"listData":[],"currentPage":1,"bottom":true},"companyData":{"profile":null,"aProfile":{"ret":0,"listingDate":"2021-12-15","address":"c/oBeOneMedicinesIGmbH,Aeschengraben27,4051Basel,Switzerland","stockEarnings":[{"period":"1week","weight":0.0407},{"period":"1month","weight":-0.0074},{"period":"3month","weight":-0.1061},{"period":"6month","weight":0.0868},{"period":"1year","weight":0.7194},{"period":"ytd","weight":0.7192}],"companyName":"百济神州有限公司","boardCode":"AI0027","perCapita":"3195股","boardName":"医药制造业","registeredCapital":"15万元","compareEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.0222},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1367},{"period":"1year","weight":0.1697},{"period":"ytd","weight":0.1695}],"survey":"　　百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。","serverTime":1766567737827,"listedPrice":192.6,"stockholders":"36008人(较上一季度增加55.74%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}}}}}